Oxurion
Oxurion NV, an integrated biopharmaceutical company, develops and commercializes medicines that address unmet clinical needs in ophthalmology in Belgium and internationally. The last earnings update was 47 days ago. More info.
Add to Portfolio Compare Print
OXUR Share Price and Events
7 Day Returns
1 Year Returns
OXUR Shareholder Return
| 7 Day | 30 Day | 90 Day | 1 Year | 3 Year | 5 Year | |
|---|---|---|---|---|---|---|
| Oxurion (OXUR) | 0.7% | -1.2% | -13% | -20.5% | 18% | -78.9% |
| BE Biotechs | 10.7% | 8.8% | 0.7% | 21.1% | 204.7% | 50.1% |
| BE Market | 0.5% | -7.5% | 2.6% | -9.3% | -14.8% | 1.5% |
1 Year Return vs Industry and Market
- OXUR underperformed the Biotechs industry which returned 21.1% over the past year.
- OXUR underperformed the Market in Belgium which returned -9.3% over the past year.
Value
Is Oxurion undervalued based on future cash flows and its price relative to the stock market?
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
undervalued.
- It is not possible to calculate the future cash flow value for Oxurion. This is due to cash flow or dividend data being unavailable. The share price is €3.81.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.The amount the stock market is willing to pay for Oxurion's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are
Oxurion's earnings available for a low price, and how does
this compare to other companies in the same industry?
| Data Point | Source | Value |
|---|---|---|
| Earnings Per Share * | Company Filings (2018-12-31) in EUR | €-1.01 |
| ENXTBR:OXUR Share Price ** | ENXTBR (2019-05-21) in EUR | €3.81 |
| Europe Biotechs Industry PE Ratio | Median Figure of 29 Publicly-Listed Biotechs Companies | 20.93x |
| Belgium Market PE Ratio | Median Figure of 86 Publicly-Listed Companies | 14.89x |
* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.
** Primary Listing of Oxurion.
| Calculation | Outcome | |
|---|---|---|
| PE Ratio | = ENXTBR:OXUR Share Price ÷ EPS (both in EUR) = 3.81 ÷ -1.01 |
-3.79x |
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Oxurion is loss making, we can't compare its value to the Europe Biotechs industry average.
- Oxurion is loss making, we can't compare the value of its earnings to the Belgium market.
Price based on expected Growth
Does
Oxurion's expected growth come at a high price?
| Data Point | Source | Value |
|---|---|---|
| PE Ratio | See PE Ratio Section | -3.79x |
| Net Income Annual Growth Rate | See Future Growth Section. Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts |
Not available |
| Europe Biotechs Industry PEG Ratio | Median Figure of 23 Publicly-Listed Biotechs Companies | 1.22x |
| Belgium Market PEG Ratio | Median Figure of 41 Publicly-Listed Companies | 1.82x |
*Line of best fit is calculated by linear regression .
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Unable to calculate PEG ratio for Oxurion, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on
Oxurion's
assets?
| Data Point | Source | Value |
|---|---|---|
| Book Value per Share | Company Filings (2018-12-31) in EUR | €2.74 |
| ENXTBR:OXUR Share Price * | ENXTBR (2019-05-21) in EUR | €3.81 |
| Belgium Biotechs Industry PB Ratio | Median Figure of 6 Publicly-Listed Biotechs Companies | 2.89x |
| Belgium Market PB Ratio | Median Figure of 120 Publicly-Listed Companies | 1.54x |
| Calculation | Outcome | |
|---|---|---|
| PB Ratio | = ENXTBR:OXUR Share Price ÷ Book Value per Share (both in EUR) = 3.81 ÷ 2.74 |
1.39x |
* Primary Listing of Oxurion.
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Oxurion is good value based on assets compared to the BE Biotechs industry average.
Value checks
We assess Oxurion's value by looking at:- Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
- Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
- Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
- Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check) Oxurion has a total score of 1/6, see the detailed checks below.
Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.
Full details on the Value part of the Simply Wall St company analysis model.
Future Performance
How is Oxurion expected to perform in the next 1 to 3 years based on estimates from 0 analysts?
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Oxurion has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.
Show me the analysis anyway
The future performance of a company is measured in the same way as past
performance, by looking at estimated
growth
and how much profit it is expected to make.Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Earnings growth vs Low Risk Savings
- Unable to compare Oxurion's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
- Unable to compare Oxurion's earnings growth to the Belgium market average as no estimate data is available.
- Unable to compare Oxurion's revenue growth to the Belgium market average as no estimate data is available.
Annual Growth Rates Comparison
| Data Point | Source | Value (per year) |
|---|---|---|
| Belgium Biotechs Industry Earnings Growth Rate | Market Cap Weighted Average | 51.3% |
| Belgium Biotechs Industry Revenue Growth Rate | Market Cap Weighted Average | 46.6% |
| Belgium Market Earnings Growth Rate | Market Cap Weighted Average | 9.6% |
| Belgium Market Revenue Growth Rate | Market Cap Weighted Average | 3.8% |
*Line of best fit is calculated by linear regression .
Industry and Market average data is calculated daily.
Learn more about our growth rate calculations in Simply Wall St’s analysis model.
Analysts growth expectations
| Data Point | Source | Value |
|---|---|---|
| Past Financials | Company Filings (4 months ago) | See Below |
| Future Estimates | Average of up to 0 Analyst Estimates (S&P Global) | See Below |
| Date (Data in EUR Millions) | Revenue | Cash Flow | Net Income * | Avg. No. Analysts |
|---|
| Date (Data in EUR Millions) | Revenue | Cash Flow | Net Income * |
|---|---|---|---|
| 2018-12-31 | 5 | -31 | -38 |
| 2018-09-30 | 6 | -7 | -8 |
| 2018-06-30 | 10 | 16 | 23 |
| 2018-03-31 | 10 | 21 | 23 |
| 2017-12-31 | 6 | 26 | 23 |
| 2017-09-30 | 6 | 0 | -19 |
| 2017-06-30 | 6 | -27 | -61 |
| 2017-03-31 | 6 | -23 | -60 |
| 2016-12-31 | 7 | -20 | -60 |
| 2016-09-30 | 8 | -20 | -47 |
| 2016-06-30 | 9 | -21 | -34 |
| 2016-03-31 | 10 | -24 | -36 |
*GAAP earnings excluding extraordinary items.
Past and Future Earnings per Share
| Data Point | Source | Value |
|---|---|---|
| Past Financials | Company Filings (4 months ago) | See Below |
| Future Estimates | Average of up to 0 Analyst Estimates (S&P Global) | See Below |
All data from Oxurion Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.
| Date (Data in EUR Millions) | EPS * | EPS High Estimate | EPS Low Estimate | Avg. No. Analysts |
|---|
| Date (Data in EUR Millions) | EPS * |
|---|---|
| 2018-12-31 | -1.01 |
| 2018-09-30 | -0.21 |
| 2018-06-30 | 0.62 |
| 2018-03-31 | 0.62 |
| 2017-12-31 | 0.63 |
| 2017-09-30 | -0.52 |
| 2017-06-30 | -1.67 |
| 2017-03-31 | -1.67 |
| 2016-12-31 | -1.67 |
| 2016-09-30 | -1.31 |
| 2016-06-30 | -0.94 |
| 2016-03-31 | -0.99 |
*GAAP earnings excluding extraordinary items.
Performance in 3 years
In the same way as past performance we look at the future estimated return
(profit) compared to the available
funds. We do this looking forward 3 years.
- Unable to establish if Oxurion will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
Future performance checks
We assess Oxurion's future performance by looking at:- Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
- Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Belgium market? (1 check)
- Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Belgium market? (1 check)
- Is the annual earnings growth rate expected to be above 20%? (1 check)
- Is the annual revenue growth rate expected to be above 20%? (1 check)
- Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Oxurion has a total score of 0/6, see the detailed checks below.
Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.
Full details on the Future part of the Simply Wall St company analysis model.
Past Performance
How has Oxurion performed over the past 5 years?
The past performance of a company can be measured by how much
growth
it has experienced and how much profit it makes relative to the funds and assets
it has available.
Past earnings growth
Past Earnings growth analysis
- Oxurion does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.
- Unable to compare Oxurion's 1-year earnings growth to the 5-year average as it is not currently profitable.
- Unable to compare Oxurion's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
All data from Oxurion Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.
| Date (Data in EUR Millions) | Revenue | Net Income * | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 2018-12-31 | 5.32 | -38.47 | 12.57 | 29.52 |
| 2018-09-30 | 6.07 | -7.75 | 11.61 | 27.76 |
| 2018-06-30 | 10.06 | 22.97 | 10.65 | 25.99 |
| 2018-03-31 | 9.56 | 22.88 | 10.56 | 24.59 |
| 2017-12-31 | 5.81 | 22.79 | 10.47 | 23.19 |
| 2017-09-30 | 5.84 | -18.86 | 10.49 | 23.22 |
| 2017-06-30 | 5.87 | -60.51 | 10.50 | 23.24 |
| 2017-03-31 | 6.49 | -60.41 | 10.68 | 23.98 |
| 2016-12-31 | 7.10 | -60.31 | 10.85 | 24.71 |
| 2016-09-30 | 8.15 | -47.02 | 13.81 | 23.91 |
| 2016-06-30 | 9.20 | -33.72 | 16.78 | 23.12 |
| 2016-03-31 | 10.20 | -35.80 | 21.19 | 22.25 |
| 2015-12-31 | 11.20 | -37.88 | 25.59 | 21.39 |
| 2015-09-30 | 11.90 | -42.16 | 29.97 | 21.31 |
| 2015-06-30 | 12.61 | -46.45 | 34.35 | 21.23 |
| 2015-03-31 | 13.19 | -48.78 | 36.87 | 21.89 |
| 2014-12-31 | 13.78 | -51.12 | 39.39 | 22.55 |
| 2014-09-30 | 15.49 | -51.59 | 40.29 | 24.28 |
| 2014-06-30 | 17.21 | -52.06 | 41.19 | 26.00 |
| 2014-03-31 | 64.99 | -12.83 | 45.20 | 28.87 |
| 2013-12-31 | 112.78 | 26.40 | 49.20 | 31.73 |
| 2013-09-30 | 107.76 | 27.63 | 47.42 | 27.38 |
| 2013-06-30 | 102.75 | 28.87 | 45.63 | 23.02 |
| 2013-03-31 | 88.93 | 29.64 | 36.21 | 19.56 |
| 2012-12-31 | 75.11 | 30.42 | 26.79 | 16.10 |
| 2012-09-30 | 75.11 | 37.58 | 21.28 | 17.87 |
| 2012-06-30 | 75.12 | 44.74 | 15.77 | 19.64 |
*GAAP earnings excluding extraordinary items.
Performance last year
We want to ensure a company is making the most of what it has available. This is
done by comparing the return (profit) to a company's available
funds,
assets
and
capital.
- It is difficult to establish if Oxurion has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
- It is difficult to establish if Oxurion has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
- It is difficult to establish if Oxurion improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
Past performance checks
We assess Oxurion's performance over the past 5 years by checking for:- Has earnings increased in past 5 years? (1 check)
- Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
- Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
- Is the Return on Equity (ROE) higher than 20%? (1 check)
- Is the Return on Assets (ROA) above industry average? (1 check)
- Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
Oxurion has a total score of 0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
Full details on the Past part of the Simply Wall St company analysis model.
Health
How is Oxurion's financial health and their level of debt?
A company's financial position is much like your own financial position,
it includes everything you own
(assets)
and owe
(liabilities).The boxes below represent the relative size of what makes up Oxurion's finances.
The net worth of a company is the difference between its assets and liabilities.
- Oxurion is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
- Oxurion has no long term commitments.
Balance sheet
Assets
Liabilities and shares
- Low level of unsold assets.
- Oxurion has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t
bad,
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
All data from Oxurion Company Filings, last reported 4 months ago.
| Date (Data in EUR Millions) | Total Equity | Total Debt | Cash & Short Term Investments |
|---|---|---|---|
| 2018-12-31 | 105.31 | 0.00 | 85.13 |
| 2018-09-30 | 105.31 | 0.00 | 85.13 |
| 2018-06-30 | 128.08 | 0.00 | 101.43 |
| 2018-03-31 | 128.08 | 0.00 | 101.43 |
| 2017-12-31 | 133.36 | 0.00 | 105.73 |
| 2017-09-30 | 133.36 | 0.00 | 105.73 |
| 2017-06-30 | 94.73 | 0.00 | 65.14 |
| 2017-03-31 | 94.73 | 0.00 | 65.14 |
| 2016-12-31 | 109.86 | 0.00 | 80.07 |
| 2016-09-30 | 109.86 | 0.00 | 80.07 |
| 2016-06-30 | 155.05 | 0.00 | 91.49 |
| 2016-03-31 | 155.05 | 0.00 | 91.49 |
| 2015-12-31 | 170.02 | 0.00 | 101.39 |
| 2015-09-30 | 170.02 | 0.00 | 101.39 |
| 2015-06-30 | 188.54 | 0.00 | 113.29 |
| 2015-03-31 | 188.54 | 0.00 | 113.29 |
| 2014-12-31 | 208.01 | 0.00 | 127.08 |
| 2014-09-30 | 208.01 | 0.00 | 127.08 |
| 2014-06-30 | 234.93 | 0.00 | 148.77 |
| 2014-03-31 | 234.93 | 0.00 | 148.77 |
| 2013-12-31 | 258.77 | 0.00 | 172.36 |
| 2013-09-30 | 258.77 | 0.00 | 172.36 |
| 2013-06-30 | 286.69 | 0.00 | 193.55 |
| 2013-03-31 | 286.69 | 0.00 | 193.55 |
| 2012-12-31 | 227.97 | 0.00 | 148.23 |
| 2012-09-30 | 227.97 | 0.00 | 148.23 |
| 2012-06-30 | 250.42 | 0.00 | 186.07 |
- Oxurion has no debt.
- Oxurion has not taken on any debt in the past 5 years.
CASH RUNWAY ANALYSIS
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
- Oxurion has sufficient cash runway for 2.7 years based on current free cash flow.
- Oxurion has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of -49.3% each year.
Financial health checks
We assess Oxurion's financial health by checking for:- Are short term assets greater than short term liabilities? (1 check)
- Are short term assets greater than long term liabilities? (1 check)
- Has the debt to equity ratio increased in the past 5 years? (1 check)
- Is the debt to equity ratio over 40%? (1 check)
- Is the debt covered by operating cash flow? (1 check)
- Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check) Oxurion has a total score of 6/6, see the detailed checks below.
- Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
- Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
Full details on the Health part of the Simply Wall St company analysis model.
Dividends
What is Oxurion's current dividend yield, its reliability and sustainability?
Dividends are regular cash payments to you from the company, similar to a
bank paying you interest on a savings account.
Annual Dividend Income
If you bought
€2,000 of
Oxurion
shares you are expected to receive
€0
in your first year as a dividend.
Dividend Amount
- Unable to evaluate Oxurion's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
- Unable to evaluate Oxurion's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not
wildly increasing/decreasing each year. This graph shows you the historical rate
to count toward your assessment of the stock.We also check to see if the dividend has increased in the past 10 years.
| Data Point | Source | Value |
|---|---|---|
| Past Annualized Dividend Yield | S&P Global Market Data | See Below |
| Past Dividends per Share | Company Filings/ Annualized Dividend Payments | See Below |
| Future Dividends per Share Estimates | Average of up to 0 Analyst Estimates (S&P Global) | See Below |
| Europe Biotechs Industry Average Dividend Yield | Market Cap Weighted Average of 9 Stocks | 0.8% |
| Belgium Market Average Dividend Yield | Market Cap Weighted Average of 78 Stocks | 3.7% |
| Belgium Minimum Threshold Dividend Yield | 10th Percentile | 1.2% |
| Belgium Bottom 25% Dividend Yield | 25th Percentile | 2.4% |
| Belgium Top 25% Dividend Yield | 75th Percentile | 4.9% |
Industry and Market average data is calculated daily.
Note all dividend per share amounts are annualized and not quarterly or other period.
| Date (Data in €) | Dividend per Share (annual) | Avg. No. Analysts |
|---|
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Unable to perform a dividend volatility check as Oxurion has not reported any payouts.
- Unable to verify if Oxurion's dividend has been increasing as the company has not reported any payouts.
Income/ dividend checks
We assess Oxurion's dividend by checking for:- Firstly is the company paying a notable dividend (greater than 1.2%) - if not then the rest of the checks are ignored.
- Is current dividend yield above the bottom 25% of dividend payers? (1 check)
- Is current dividend yield above the top 25% of dividend payers? (1 check)
- Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
- If they have paid a dividend for 10 years has it increased in this time? (1 check)
- How sustainable is the dividend, can Oxurion afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks) Oxurion has a total score of 0/6, see the detailed checks below.
Full details on the Dividends part of the Simply Wall St company analysis model.
Management
CEO
| COMPENSATION | €560,000 |
| TENURE AS CEO | 10.7 years |
CEO Bio
Dr. Patrik De Haes, ViBio, BVBA, MD, has been the Chief Executive Officer of ThromboGenics NV since September 1, 2008. Dr. De Haes serves as an Executive Director of ThromboGenics NV. Dr. Haes serves as Executive Director, Acting CMO and Chief Executive Officer of Oxurion NV. Dr. De Haes served as the Chief Operating Officer of ThromboGenics NV until September 1, 2008. Previously, he served as Head of the Global Insulin Infusion business at Roche in Switzerland. He served as President and Chief Executive Officer of Disetronic Medical Systems Inc., a leading company in insulin infusion therapy, in Minneapolis, USA. At Sandoz Pharma (Now Novartis) in Switzerland, he led The Global Development and Commercialization of the First Biotech Product for it. He has over 20 years of experience in The Global Health Care Industry, Covering Product Development, Marketing and General Management. Dr. De Haes holds a degree in Medicine from the University of Leuven and a corporate MBA from the University of St. Thomas, Minneapolis, USA. Dr. De Haes holds degree in Marketing Strategy from INSEAD, Fontainebleau, France and MD degree from KULeuven, Belgium.
CEO Compensation
- Patrik's compensation has increased whilst company is loss making.
- Patrik's remuneration is higher than average for companies of similar size in Belgium.
Management Team Tenure
Average tenure of the Oxurion management team in years:
- The tenure for the Oxurion management team is about average.
Management Team
Patrik De Haes
CEO, Acting CMO & Executive Director
€560K
10.7 yrs
Dominique Vanfleteren
Chief Financial Officer
4.3 yrs
Jean Feyen
Chief Scientific Officer
Wouter Piepers
Global Head of Corporate Communications & Investor Relations
Claude Sander
Chief Legal Officer
Isabelle Decoster
Head of HR
Andy De Deene
Global Head of Development
Ove Pedersen
Head of Product Supply
61
Marc Denayer
Global Head of Drug Safety & Medical Affairs
2.8 yrs
Vinciane Vangeersdaele
Chief Commercial Officer
1.5 yrs
Board of Directors Tenure
Average tenure and age of the Oxurion board of directors in years:
- The tenure for the Oxurion board of directors is about average.
Board of Directors
Thomas Clay
Chairman
€35K
33
1.9 yrs
Patrik De Haes
CEO, Acting CMO & Executive Director
€560K
Emmanuele Attout
Non-Executive Independent Director
€30K
4 yrs
David Guyer
Non-Executive Director
€99K
58
5.4 yrs
Philippe Vlerick
Non-Executive Independent Director
€18K
63
3.8 yrs
Adrienne Graves
Director
65
0.6 yrs
Who owns this company?
Recent Insider Transactions
| Announced | Type | Name | Entity | Role | Start | End | Shares | Max Price (€) | Value (€) | |
|---|---|---|---|---|---|---|---|---|---|---|
Management checks
We assess Oxurion's management by checking for:- Is the CEO's compensation unreasonable compared to market cap? (1 check)
- Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
- Is the average tenure of the management team less than 2 years? (1 check)
- Is the average tenure of the board of directors team less than 3 years? (1 check) Oxurion has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.
Note: We use the top 6 management executives and board members in our calculations.
Note 2: Insider trading include any internal stakeholders and these transactions .
Full details on the Management part of the Simply Wall St company analysis model.
News
Simply Wall St News
Can We See Significant Insider Ownership On The Oxurion NV (EBR:OXUR) Share Register?
Large companies usually have institutions as shareholders, and we usually see insiders owning shares in smaller companies. … Oxurion is a smaller company with a market capitalization of €147m, so it may still be flying under the radar of many institutional investors. … institutional investors have not yet purchased much of the company.
Simply Wall St - – Full articleDoes Market Volatility Impact Oxurion NV's (EBR:OXUR) Share Price?
If you're interested in Oxurion NV (EBR:OXUR), then you might want to consider its beta (a measure of share price volatility) in order to understand how the stock could impact your portfolio. … Beta is a widely used metric to measure a stock's exposure to market risk (volatility). … The first thing to understand about beta is that the beta of the overall market is one.
Simply Wall St - – Full articleDid You Manage To Avoid Oxurion's Devastating 79% Share Price Drop?
Oxurion NV (EBR:OXUR) shareholders should be happy to see the share price up 15% in the last month. … In fact the share price has glided down a mountain to land 79% lower after that period. … During five years of share price growth, Oxurion moved from a loss to profitability.
Simply Wall St - – Full articleIs Oxurion NV (EBR:OXUR) Overpaying Its CEO?
This report will, first, examine the CEO compensation levels in comparison to CEO compensation at companies of similar size. … The aim of all this is to consider the appropriateness of CEO pay levels. … How Does Patrik De Haes's Compensation Compare With Similar Sized Companies?
Simply Wall St - – Full articleWhat You Must Know About Oxurion NV's (EBR:OXUR) Financial Strength
The direct benefit for Oxurion NV (EBR:OXUR), which sports a zero-debt capital structure, to include debt in its capital structure is the reduced cost of capital. … Does OXUR's growth rate justify its decision for financial flexibility over lower cost of capital … Debt capital generally has lower cost of capital compared to equity funding.
Simply Wall St - – Full articleIs Oxurion NV's (EBR:OXUR) 18% ROE Strong Compared To Its Industry?
This article is for those who would like to learn about Return On Equity (ROE). … That means that for every €1 worth of shareholders' equity, it generated €0.18 in profit. … Return on Equity = Net Profit ÷ Shareholders' Equity
Simply Wall St - – Full articleCould The Oxurion NV (EBR:OXUR) Ownership Structure Tell Us Something Useful?
Oxurion is not a large company by global standards. … Our analysis of the ownership of the company, below, shows that. … institutional investors have bought into the company.
Simply Wall St - – Full articleDoes Oxurion NV (EBR:OXUR) Have A Particularly Volatile Share Price?
Modern finance theory considers volatility to be a measure of risk, and there are two main types of price volatility. … Some investors use beta as a measure of how much a certain stock is impacted by market risk (volatility). … A stock with a beta greater than one is more sensitive to broader market movements than a stock with a beta of less than one.
Simply Wall St - – Full articleWhy Oxurion NV's (EBR:OXUR) CEO Salary Matters To You
First, this article will compare CEO compensation with compensation at similar sized companies. … How Does Patrik De Haes's Compensation Compare With Similar Sized Companies. … Thus we can conclude that Patrik De Haes receives more in total compensation than the median of a group of companies in the same market, and of similar size to Oxurion NV
Simply Wall St - – Full articleCompany Info
Description
Oxurion NV, an integrated biopharmaceutical company, develops and commercializes medicines that address unmet clinical needs in ophthalmology in Belgium and internationally. The company’s lead product is JETREA used for the treatment of symptomatic vitreomacular adhesion and vitreomacular traction. It also develops THR-317, a placental growth factor (PIGF) neutralizing monoclonal antibody that is in Phase I/II clinical study for the treatment of diabetic macular edema (DME) or diabetic retinopathy (DR); THR-149, a plasma kallikrein inhibitor for treatment of DME; THR-687 a small molecule integrin antagonist to treat patients with DR and/or DME; and TB-403, an anti-PlGF for treatment of medulloblastoma, a pediatric malignant brain tumor. Oxurion NV has collaboration agreements with BioInvent International AB, Bicycle Therapeutics, Outcome Sciences, Inc., Parexel, INC Research, Galapagos, and Beta Therapeutics Pty Ltd. The company was formerly known as ThromboGenics NV and changed its name to Oxurion NV in September 2018. Oxurion NV was founded in 1991 and is headquartered in Leuven, Belgium.
Details
| Name: | Oxurion NV |
| OXUR | |
| Exchange: | ENXTBR |
| Founded: | 1991 |
| €145,892,329 | |
| 38,291,950 | |
| Website: | http://www.oxurion.com |
| Address: |
Oxurion NV Gaston Geenslaan 1, Leuven, Flemish Brabant, 3001, Belgium |
Listings
| Exchange Symbol | Ticker Symbol | Security | Exchange | Country | Currency | Listed on | |
|---|---|---|---|---|---|---|---|
| ENXTBR | OXUR | Ordinary Bearer Shares | Euronext Brussels | BE | EUR | 07. Jul 2006 | |
| OTCPK | TBGN.F | Ordinary Bearer Shares | Pink Sheets LLC | US | USD | 07. Jul 2006 | |
| DB | TG4 | Ordinary Bearer Shares | Deutsche Boerse AG | DE | EUR | 07. Jul 2006 | |
| LSE | 0G99 | Ordinary Bearer Shares | London Stock Exchange | GB | EUR | 07. Jul 2006 |
Number of employees
Current staff
Industry
| Biotechnology | |
| Pharmaceuticals & Biotech |
Company Analysis and Financial Data Status
| Area | Date (UTC time) |
|---|---|
| Company Analysis updated: | 2019/05/21 21:11 |
| End of day share price update: | 2019/05/21 00:00 |
| Last estimates confirmation: | 2019/03/07 |
| Last earnings filing: | 2019/04/04 |
| Last earnings reported: | 2018/12/31 |
| Last annual earnings reported: | 2018/12/31 |
All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
